Starpharma Holdings announced the signing of a pharma alliances agreement with global pharmaceutical company AstraZeneca.
This pharma alliances pact will give AstraZeneca the right to test certain proprietary Starpharma oncology molecules based on Starpharma’s dendrimer technology.
Under the pharma alliances agreement AstraZeneca will undertake oncology studies using specific Starpharma drug-dendrimer conjugate molecules.
The primary objective of the program is to assess the suitability of the dendrimer constructs for particular applications within the cancer field.
Further details of the pharma alliances pact between the parties were not disclosed.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity